2026-04-29T05:37:36Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/163862025-06-09T15:02:40Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19612col_20.500.12105_16978col_20.500.12105_16988
Repisalud
author
Valero, Marta
author
Sanchez-Piedra, Carlos
author
Freire, Mercedes
author
Colazo, María
author
Busquets, Noemí
author
Meriño-Ibarra, Erardo
author
Rodríguez-Lozano, Carlos
author
Manrique, Sara
author
Campos, Cristina
author
Sánchez-Alonso, Fernando
author
Castrejón, Isabel
funder
Sociedad Española de Reumatología
funder
Agencia Española de Medicamentos y Productos Sanitarios
funder
Bristol-Myers Squibb
funder
Janssen Cilag
funder
Eli Lilly
funder
Merck, Sharp & Dohme
funder
Novartis
funder
Pfizer
funder
Regeneron (Estados Unidos)
funder
Biogen
funder
Celltrion
funder
Samsung Bioepis
2023-08-31T17:10:08Z
2023-08-31T17:10:08Z
2023-05-22
Arthritis Res Ther. 2023 May 22;25(1):86.
http://hdl.handle.net/20.500.12105/16386
37217997
10.1186/s13075-023-03045-3
1478-6362
Arthritis research & therapy
Background: The objectives of this study were to assess the discontinuation of biologic therapy in patients who achieve remission and identify predictors of discontinuation of biologics in patients with inflammatory arthritis in remission. Methods: An observational retrospective study from the BIOBADASER registry comprising adult patients diagnosed with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) and receiving 1 or 2 biological disease-modifying drugs (bDMARDs) between October 1999 and April 2021. Patients were followed yearly after initiation of therapy or until discontinuation of treatment. Reasons for discontinuation were collected. Patients who discontinued bDMARDs because of remission as defined by the attending clinician were studied. Predictors of discontinuation were explored using multivariable regression models. Results: The study population comprised 3,366 patients taking 1 or 2 bDMARDs. Biologics were discontinued owing to remission by 80 patients (2.4%): 30 with RA (1.7%), 18 with AS (2.4%), and 32 with PsA (3.9%). The factors associated with a higher probability of discontinuation on remission were shorter disease duration (OR: 0.95; 95% CI: 0.91-0.99), no concomitant use of classic DMARDs (OR: 0.56; 95% CI: 0.34-0.92), and shorter usage of the previous bDMARD (before the decision to discontinue biological therapy) (OR: 1.01; 95% CI: 1.01-1.02); in contrast, smoking status (OR: 2.48; 95% CI: 1.21-5.08) was associated with a lower probability. In patients with RA, positive ACPA was associated with a lower probability of discontinuation (OR: 0.11; 95% CI: 0.02-0.53). Conclusions: Discontinuation of bDMARDs in patients who achieve remission is uncommon in routine clinical care. Smoking and positive ACPA in RA patients were associated with a lower probability of treatment discontinuation because of clinical remission.
eng
Biologic DMARD
Discontinuation
Real-world evidence
Remission
Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry
research article
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
URL
https://repisalud.isciii.es/bitstreams/34b5675b-dcf3-4dcb-8cd4-436619cc2eac/download
File
MD5
ed2f91970d23ef13dee746a248c6f99d
829089
application/pdf
FactorsAssociatedDiscontinuationBiologics_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/548b5d31-1c34-4fe5-9b0e-63f113977ab9/download
File
MD5
78e341dcc1085baef238fd1a28e9b3b0
656138
application/pdf
Correction_FactorsAssociatedDiscontinuation_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/e1049a66-a9c2-495c-a4b2-d27b6caae630/download
File
MD5
ce2e61a664f4231899fb54402353c7c4
547469
application/pdf
Supplementary_t1_FactorsAssociatedDiscontinuationBiologics_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/6d1df55a-cd50-4cbe-9c66-7ce25a436ea8/download
File
MD5
cd363df67fa7b9cf51fa8001fb1aa70f
484152
application/pdf
Supplementary_t2_FactorsAssociatedDiscontinuationBiologics_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/ad5a2ac6-3858-4e47-aed0-6c6167265d5b/download
File
MD5
9ec0ab1bca6823dda27b42a7302a8d7f
495117
application/pdf
Supplementary_t3_FactorsAssociatedDiscontinuationBiologics_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/d1885c36-e579-4cc1-8e0f-bab1768feabc/download
File
MD5
287aaa2c5252d1d5830392ff0ab0dd59
571000
application/pdf
Supplementary_t4_FactorsAssociatedDiscontinuationBiologics_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/60dba0bd-d85e-4f7a-ba84-9feefa572f1d/download
File
MD5
a3ba02b9671c09823b8a6464af410b47
460161
application/pdf
Supplementary_t5_FactorsAssociatedDiscontinuationBiologics_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/e9697dc6-738d-4389-a673-57345ea1fa88/download
File
MD5
ea28a64ca9eac390188ed51420b689b3
458859
application/pdf
Supplementary_t6_FactorsAssociatedDiscontinuationBiologics_2023.pdf
URL
https://repisalud.isciii.es/bitstreams/bf07dfd4-5555-4ca1-93b4-a9fefdb39ef0/download
File
MD5
0d9c7f83053d17b6af18a4fdc9f25e20
52012
text/plain
FactorsAssociatedDiscontinuationBiologics_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/da839a4a-a844-414d-98ac-582b38860975/download
File
MD5
0f8a56da9df2f61d7f787a9123455111
3256
text/plain
Supplementary_t1_FactorsAssociatedDiscontinuationBiologics_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/a5a5a5b1-0d26-45ce-b2ac-3aa068a25832/download
File
MD5
a20b839f4cbb763e29d0526b7690f6e6
2322
text/plain
Supplementary_t2_FactorsAssociatedDiscontinuationBiologics_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/3f4630bf-91da-43f8-9507-1feaa75c7827/download
File
MD5
ebbab11e55b3299989757cd9b34420f5
2263
text/plain
Supplementary_t3_FactorsAssociatedDiscontinuationBiologics_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/528d2808-c628-43b5-8d04-62a995cbde9d/download
File
MD5
3dd8af5464db283d381ae10c8d36b08b
4605
text/plain
Supplementary_t4_FactorsAssociatedDiscontinuationBiologics_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/67016447-bb10-42b0-a91f-8b3c98f307e4/download
File
MD5
bbb6486f177af5f9b4c8fee29327d8c5
1507
text/plain
Supplementary_t5_FactorsAssociatedDiscontinuationBiologics_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/db8773f9-9ae6-4241-88c2-18ef06e5b50a/download
File
MD5
ad1bf12af914f014c5f0493d5c278501
1529
text/plain
Supplementary_t6_FactorsAssociatedDiscontinuationBiologics_2023.pdf.txt
URL
https://repisalud.isciii.es/bitstreams/4ae6348a-50a1-4c2e-bf32-6d42f3367d8c/download
File
MD5
95dac3b15ead83c10f447a8a1cc563b9
4142
text/plain
Correction_FactorsAssociatedDiscontinuation_2023.pdf.txt